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Transgenic mice bearing the human poliovirus receptor (TgPVR) are less susceptible to oral inoculation, although they are susceptible to
parenteral inoculation. We investigated the susceptibility of TgPVR 21 line [Arch. Virol. 130 (1994) 351] to poliovirus through various
mucosal routes. Intranasal inoculation of a neurovirulent Mahoney strain (OM1) caused flaccid paralysis with viral replication in the central
nervous system at a dose of 106 cell culture infectious dose (CCID50), in contrast, no paralysis following oral or intragastric inoculation of the
same dose. Intranasal inoculation of a vaccine strain, Sabin 1, at 106 CCID50, resulted in no paralysis. Initial replication of poliovirus in the
nasal cavity was confirmed by virus isolation and detection of negative-stranded replicative intermediates by RT-PCR and viral antigens using
a high-sensitive immunohistochemistry and genome/transcripts by in situ hybridization. Poliovirus-specific IgG antibodies were elevated in
the sera of surviving TgPVR21. This model can be used as a mucosal infection model and for differentiation of neurovirulent and attenuated
poliovirus strains.
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Introduction cells, nonhuman primates were shown to be susceptible toPoliomyelitis caused by polioviruses, members of entero-
virus genus, is going to be eradicated by the global program
of vaccination using oral poliovirus vaccines (OPV) and
surveillance of acute flaccid paralysis. However, the patho-
genesis of poliovirus infection is not completely understood
because of the absence of suitable animal models of polio-
myelitis. In humans, poliovirus infection is initiated by oral
infection. In early researches from 1930s to 1950s before the
isolation of poliovirus by Enders et al. (1949) using cultured0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: tiwasaki@net.nagasaki-u.ac.jp (T. Iwasaki).polioviruses through direct inoculation of polioviruses into
the nervous system, or via parenteral inoculation such as
through intramuscular, intravenous, and intraperitoneal
routes. In chimpanzees and other nonhuman primates, high-
titer virus inoculation was required to cause poliomyelitis
through the oral route.
Sabin developed live vaccines for poliomyelitis in the
1940s by experimental studies using monkeys (Sabin,
1985), demonstrating high sensitivity to polioviruses
through the intranasal route. Pathological analysis
revealed the presence of poliovirus-related lesions in the
olfactory system of these monkeys, however, such lesions
had never been observed in humans and the intranasal
route has been neglected in the experimental infection of
poliovirus.
Table 2
Effect of volume of virus inocula on intranasal inoculation to TgPVR21
Volume Inoculum Number Clinical symptom Failure time
(CCID50) of mice Paralysis Death
(days p.i.)
2 Al 106 5 4 (80%) 4 (80%) 7–13
107 5 4 (80%) 4 (80%) 6–8
20 Al 106 5 3 (60%) 3 (60%) 6–14
107 5 4 (80%) 4 (80%) 5–7
N. Nagata et al. / Virology 321 (2004) 87–10088Identification and molecular cloning of human poliovirus
receptor (hPVR/CD155) was achieved (Koike et al., 1990;
Mendelsohn et al., 1989). From these studies, hPVR is
shown to be a membrane glycoprotein belonging to the
immunoglobulin superfamily. Soon, the binding site to
poliovirus was revealed to be localized in the N-terminal
domain of hPVR molecules (Aoki et al., 1994; Bernhardt et
al., 1994a, 1994b; Freistadt and Racaniello, 1991; Koike et
al., 1991a, 1991b). Transgenic mice bearing the hPVR gene
(TgPVR) driven by the original human promoter have been
demonstrated to be a good substitute for monkeys in
experimental infection of polioviruses (Horie et al., 1994).
Now, TgPVR is going to be used in neurovirulence tests for
vaccine control by the intraspinal inoculation method (Abe
et al., 1995a, 1995b; Dragunsky et al., 1996; Levenbrook et
al., 2001; Wood, 1997). While hPVR is expressed in four
isoforms, a, h, g, and y, by alternative splicing from a
single-copy gene located on human chromosome 19 (Koike
et al., 1990) in humans, TgPVR established by Koike et al.
(1990) were shown to express both hPVR-a and -y as a type
1 single-pass transmembrane glycoprotein.
The infectious routes in TgPVR are quite similar to those
in nonhuman primates. Three lines of TgPVR have been
analyzed (Koike et al., 1994). TgPVR1 was shown to be
susceptible to poliovirus through the intraspinal, intracere-
bral, intramuscular, and intravenous pathways, but not
through the oral route (Koike et al., 1994). TgPVR21 was
less susceptible through the intracerebral route because of
decreased levels of hPVR expression (Koike et al., 1994).
Previous studies of experimental infection in cynomolgus
monkeys and TgPVR1/TgPVR21 confirm the similarities of
poliovirus neuropathogenicity in these animals (Abe et al.,
1995a, 1995b; Nagata et al., 2001), and TgPVR21 has been
intended to use as substitutes for monkeys in neurovirulence
tests of poliovirus vaccine control. Recently, Crotty et al.
(2002) developed another TgPVR carrying a PVRy cDNA
driven a h-actin promoter, cPVR mice, which were shown
to be susceptible to poliovirus through intracerebral, intra-
muscular, and intranasal routes, and developed bulbar
poliomyelitis after intranasal inoculation.
In the present study, we investigated the mucosal
infection of poliovirus type 1 in TgPVR21 through intra-Table 1
Outcome of TgPVR21 mice after inoculation of Mahoney strain of
poliovirus 1 through various routes
Route/dose Inoculum Numbers Clinical symptoms Paralysis
(CCID50) of mice Paralysis Death
(days p.i.)
Intragastric/ 106 10 0 (0%) 0 (0%) >21
100 Al 107 10 0 (0%) 0 (0%) >21
108 10 0 (0%) 0 (0%) >21
Oral/150 Al 106 10 0 (0%) 0 (0%) >21
107 10 0 (0%) 0 (0%) >21
108 10 1 (10%) 1 (10%) 8
Intranasal/ 105 7 3 (42.9%) 3 (42.9%) 6–8
10 Al 106 7 3 (42.9%) 3 (42.9%) 6–8
107 7 6 (85.7%) 6 (85.7%) 6–7nasal, intraoral, and intragastric routes, and revealed that
TgPVR21 are highly susceptible to a neurovirulent strain
and resistant to a vaccine strain of poliovirus type 1
through intranasal inoculation. In addition, we preliminar-
ily analyzed induction of immunity against poliovirus after
intranasal inoculation.Results
Susceptibility of TgPVR21 infected by neurovirulent
poliovirus 1 through different routes
Initially, we determined the outcome of poliovirus 1
infection of TgPVR21 following oral, intragastric and
intranasal inoculation of a neurovirulent strain, OM1. The
mice infected through the intragastric route did not present
any clinical manifestations over a 21-day period post-
inoculation (p.i.) (Table 1). A similar outcome was observed
for mice infected via intraoral inoculation except oneFig. 1. Dose– response regression of TgPVR21 after intranasal inoculation
of poliovirus. (x-axis) Logarithmic value of inoculated virus titer. ( y-axis)
Probit transformed paralysis rate. A clearer dose– response relation was
attained in the mice inoculated with 2 Al volume (closed square) comparing
to those with 10 Al volume (closed circle).
Table 3
Time course of pathological changes of TgPVR21 intranasally inoculated
with Mahoney strain of poliovirus 1
Volume/ Days Number Nasal cavity CNS
inoculum p.i. of mice
Inflammation Viral
antigen
Inflammation Viral
antigen
2 Al/107 2 3 3 0 (3)a 0 0
CCID50 4 3 3 0 (3)
a 0 0
6 3 3 0 (3)a 1 0
7 3a 3 0 (ND)b 3 3
a Parenthesis: results of high-sensitive immunohistochemical detection after
antigen retrieval.
b ND: not done.
N. Nagata et al. / Virology 321 (2004) 87–100 89infected with an inoculum of 108 cell culture infectious dose
(CCID50) developing flaccid paralysis at day 8 p.i. and died
the next day. On the contrary, more than 40% of the miceFig. 2. Histopathology of the nasal cavity of mice. OM1 inoculated non-transgenic
post-inoculation (p.i.). Two-microliter volume of Eagle’s minimum essential m
mononuclear cells was only observed in the nasal respiratory area (arrowheads) of t
was associated with regeneration of the columnar epithelium (inset, HE; 400), bu
contrast, no particular histological changes were recognized in the nasal respira
(A and C, HE; 40, 400).infected intranasally with a 105 CCID50 inoculum developed
flaccid paralysis of the hind limbs or forelimbs from days 6
to 8 p.i. The mice infected at higher doses showed high
morbidity and mortality rates, which were quite similar.
Thus, the paralysis dose (PD50) and lethal dose (LD50) were
the same calculated to be 105.645 CCID50 with respect to
mice infected intranasally by the Probit method according to
Finney (1964).
Paralysis progressed rapidly in symptomatic TgPVR21.
The initial appearance of paralysis was various such as
hemiplegia, or paralysis of the forelimbs or hind limbs. In
addition, some mice showed lacrimation, slow movement,
gait disturbance, piloerection, and loss of body weight.
Although we observed the inoculated mice twice a day,
some morbid mice died suddenly without any preceding
manifestations even 12 h before the death.mouse BALB/c (A and C) and TgPVR21 (B and D) were examined on day 7
edium was inoculated in the mock. Focal infiltration of neutrophils and
he virus-inoculated mouse [B, hematoxylin–eosin (HE); 40]. This change
t no significant changes in the olfactory epithelium (D, HE; 40, 400). In
tory and olfactory mucosa of the OM1 inoculated non-transgenic mouse
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CCID50/100 Al from the serum of the morbid mice. In
contrast, the virus was not isolated from the serum of
asymptomatic mice. The virus was not recovered from the
intestinal contents of the paralytic mice, except one in which
a 106 CCID50 inoculum was intranasally inoculated and a
trace amount of virus was isolated on day 7 p.i.
Serum samples were obtained at 3 weeks p.i. from
surviving mice infected through oral, intragastric, and
intranasal routes, and the neutralizing antibody titer for
poliovirus 1 was determined. The neutralizing antibody titer
in the serum was less than four times dilution in all of the
surviving mice infected through any of the mucosal routes.
This suggests that poliovirus infection in these surviving
mice was not established or was insufficient to provoke a
protective immunity. We then determined the neutralizingFig. 3. Sequential changes of the nasal cavities of TgPVR21 after intranasal inoc
epithelium cells of the left nasal cavity showed minimal cytological changes su
cytoplasm of these cells using a high-sensitive immunohistochemical technique des
some blood vessels [A, hematoxylin–eosin (HE), B, immunohistochemistry (IHC)
were observed in the right side of nasal cavity (C, HE, D, IHC; 400). On day 2 p
for the poliovirus antigen (E and G, HE; and F and H, IHC; 400 and 800,
mononuclear cells infiltrated into epithelial and subepithelial layer and some epith
(I, K, HE and J, L, IHC; 400).antibody titer in the sera of four paralytic mice and found
these sera also to be negative for antibody. However, the
serum samples were obtained within 7 days p.i which was
too early to determine the neutralizing antibody titer.
Effect of volume of intranasal inoculation
The effect of the volume of the intranasal inoculum was
investigated to determine the poliovirus entry site because
poliovirus in 10 Al of inoculum might enter the body both
from the upper and lower respiratory tract. In previous
studies using influenza virus, we estimated the inoculum
volume, which induced respiratory tract infections (Iwasaki
et al., 1999). Therefore, we inoculated twenty 14-week-old
TgPVR21 using inoculum volumes, 2 and 20 Al, and
observed for 14 days. Eighty percent of the mice inoculatedulation of OM1. On day 1 p.i. into the left nasal nostril, a few of columnar
ch as swelling of cytoplasm. The poliovirus antigen was detected in the
cribed in Materials and methods. Attachment of neutrophils was observed in
; 400]. Neither histological changes nor cells positive for the viral antigen
.i., some epithelium cells showed marked swelling changes and was positive
respectively). On days 4 (I and J) and 6 (K and L) p.i., neutrophils and
elial cells are positive for the poliovirus antigen in affected epithelial cells
N. Nagata et al. / Virology 321 (2004) 87–100 91with 2 Al of poliovirus developed paralysis and died (Table
2). Appearance of paralysis was not significantly different
among these groups. From this observation, it became
apparent that poliovirus infection localized initially in the
nasal cavity can progress to central nervous system infection
(CNS). Although the relative virulence of poliovirus at 2-Fig. 4. Detection of the poliovirus genome and transcripts in OM1-infected TgPVR
B) No signals were detected in the olfactory bulb of the mouse on day 1 p.i. using a
D) Weak signals were detected in the cytoplasm of several degenerating epithelial
apparent by the antisense probe (C) but weak by the sense probe (D) (NBT/BCIP,
mouse on day 4 p.i. show strong signals in the cytoplasm (E, antisense probe), bAl inoculation to that at 10-Al inoculation was 0.415 with
95% confidence limits, 0.002–13.164, and the dose–re-
sponse relation was more correlated in the mice inoculated
with 2 Al volume than those with 10 Al (Fig. 1). Accord-
ingly, we concluded the volume of inoculation to be 2 Al in
the further studies.21 by in situ hybridization using digoxigenin-labeled RNA probes. (A and
ntisense (A) and sense (B) probes (NBT/BCIP, methyl green; 200). (C and
cells of the nasal cavity of the mouse on day 1 p.i. The signals were more
methyl green; 400). (E and F) Neuronal cells in the pons of nonparalytic
ut it was faint by sense probe (F) (NBT/BCIP, methyl green; 400).
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To confirm poliovirus infection in the nasal cavities and
CNS, we sequentially autopsied three TgPVR21 on days 2,
4, 6, and 7 p.i. after intranasal inoculation of attenuated and
neurovirulent strains of poliovirus 1 and examined them for
histological lesions and the poliovirus antigen using an
immunohistochemical method (Table 3). In this experiment,
no apparent clinical manifestations were recognized in mice
infected with the attenuated strain, Sabin 1. Mice infected
with OM1 did not show any manifestations before paralysis
around day 7 p.i. On day 7 p.i., inflammatory lesions were
observed in the mucosal surface of the respiratory area of all
mice inoculated with OM1 at 107 CCID50 (Fig. 2B). We
examined the sequential changes. On day 1 p.i., minimal
epithelial changes were observed in the mucosa only in the
inoculated side (Figs. 3A and C). On day 2 p.i., swelling and
pseudostratification of ciliated epithelial cells were found
with granulocytic infiltration (Figs. 3E and G). On day 4
p.i., epithelial cells became necrotic with occasional
pyknotic nuclei and subepithelial edema (Fig. 3I). Epithelial
cells were focally lost on day 6 p.i. with regeneration ofFig. 5. Histopathology of the brain of OM1-infected TgPVR21. Paralytic mice w
detected by the ABC-peroxidase method [immunohistochemistry (ICH)]. Gliosis a
200). Neurons in the vestibular nuclei were degenerative and necrotic with occ
antigen was detected in these neurons (C, IHC; 400). In the ventral horn of the c
E, HE; 200 and 400, respectively) and were positive for the viral antigen in
were also observed in the thalamus (G, HE; 400 and H, IHC; 400) and motsurrounding cells (Fig. 3K). No significant changes were
observed in the olfactory epithelium during 7 days p.i. (Fig.
2D). Although we could not detect the viral antigen in the
mucosa of both mice infected with Sabin 1 or OM1
throughout the observation period using ordinary immuno-
histochemistry, the cytoplasm of the columnar cells of the
nasal mucosa showing ballooning became positive for the
viral antigen from day 1 p.i. using a high-sensitive immu-
nohistochemical method with antigen retrieval (Fig. 3). No
staining was attained in the columnar epithelium of mouse
not infected with poliovirus. To confirm this finding, we
performed an RNA in situ hybridization analysis to detect
the poliovirus genome and transcripts. The viral genomes
and negative-stranded viral transcripts are detected very
weakly in the cytoplasm of a few epithelial cells of nasal
cavities in two out of three mice on day 1 p.i. using non-
isotopic RNA in situ hybridization (Figs. 4C and D). The
signals were strongly positive in the neurons in the pons
(Fig. 4E) on day 4 p.i. The signals obtained using the sense
probe were weaker than these by anti-sense probe (Figs.
4C–F). The epithelial localization of positive signals of the
viral genome in the nasal cavities was well correlated withere examined on day 7 after intranasal inoculation. Poliovirus antigen was
nd vascular cuffing (arrowheads) were prominent in the brainstem (A, HE;
asionally neuronophagia [B, hematoxylin–eosin (HE); 400]. Poliovirus
ervical spinal cord, many neurons became degenerative and necrotic (D and
the cytoplasm (F, IHC; 400). Degenerative and antigen-positive neurons
or cortex (I, HE; 400, J, ABC; 400).
Table 4
Localization of virus antigen in the TgPVR21 mice after intranasal
inoculation with wild poliovirus 1, Mahoney strain
Localization Virus antigen
One day
p.i.
(N = 3)
Paralyzed
mice
(N = 3)
Spinal cord lumbar anterior horn  +
intermediate  +
posterior horn  +
white matter  
cervical anterior horn  +
intermediate  +
posterior horn  +
white matter  
Inferior olive  
Reticular
formation
 
Pontine nuclei  +
Cerebellum cortex  
nuclei  +
Superior and
inferior
colliculi
 +
Red nuclei  +
Substantia nigra  +
Thalamus  +
Basal ganglia  
Internal capsule  
Hippocampus
and amygdala
 
Motor cortex  +
Sensory cortex  
Parietal and
occipital
cortex
 
I olfactory nerve  
II optic nerve  
III oculomotor nerve  
IV trochlear nerve ND ND
V trigeminal nerve
and ganglia
 +
VI abducens nerve  +
VII facial nerve  +
VIII vestibulocochlear
nerve
 ND
IX glossopharyngeal
nerve
ND ND
X vagus nerve  
XI spinal accessory
nerve
ND ND
XII hypoglossal nerve  
Dorsal root
ganglia
 +
ND: not determined.
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infection of poliovirus. The sensitivity was more excellent
in the high-sensitive immunohistochemical analysis than in
the in situ hybridization analysis. No positive signals were
obtained in the olfactory bulbs during the time course (Figs.
4A and B) except the paralytic mice.
CNS lesions, such as neuronal degeneration, loss of
neurons and neuronophagia, were conspicuous in all of
the three paralytic mice examined on day 7 p.i. These
lesions were not observed in asymptomatic mice except
one. In this mouse examined on day 6 p.i., neuronal
degeneration with inflammatory changes was observed in
the pons and was considered to be an early lesion before the
onset of paralysis. The most marked cytological changes
appeared in the vestibular nuclei in the brainstem (Figs. 5A
and B) and the motor neuron of the cervical spinal cord
(Figs. 5D and E). In particular, cellular infiltration was
prominent around and within the vestibular nuclei. On the
contrary, thalamic (Fig. 5G) and cortical (Fig. 5I) changes
were not significant. A few mononuclear cells infiltrated in
the subarachnoid space of symptomatic mice.
To further clarify the pattern of viral infection in CNS,
we performed the immunohistochemical analysis. The anti-
gen was detected only in the neurons of mice showing
paralysis (Figs. 5C, F, H, and J). The antigen-positive
neurons distributed in the spinal cord (Fig. 5F), brain nerve
nuclei, cerebellar nuclei, brainstem (Fig. 5C), diencephalon
(Fig. 5H), and cerebral cortex (Fig. 5J) (Table 4). In the
spinal cord, not only the motor neurons but also neurons in
the lateral and posterior horns were infected. The pyramidal
cells in the motor cortex were also antigen-positive. The
antigen-positive cells were also detected in the trigeminal
and dorsal root ganglia. In these paralytic mice, the antigen
was not detected in the glial, ependymal, meningeal nor
endothelial cells. In asymptomatic TgPVR21 mice exam-
ined on days 1 and 2, 4 and 6 p.i., no antigen-positive cells
were detected in CNS. When we examined these asymp-
tomatic mice using the high-sensitive immunohistochemis-
try and in situ hybridization, the positive cells were
recognized only in the pons and medulla of some mice on
days 4 and 6 p.i.
BALB/c mice were investigated as negative controls. We
inoculated these mice with 2 Al of OM1 at 107 CCID50 and
examined them on day 7 p.i. No significant changes were
observed either in CNS or maxillary cavities of BALB/c
mice (Figs. 2A and C) and poliovirus antigen-positive cells
were not detected in these tissues.
Time course of poliovirus replication in TgPVR21
Ordinary immunohistochemical analysis revealed the
presence of cells positive for poliovirus capsid antigen only
in paralytic mice. To confirm virus replication following
intranasal inoculation, we determined the virus titer in
various tissues. Twenty TgPVR21 mice were inoculated
with 2 Al of OM1 at 107.21 CCID50 and three to four micewere examined at 6 h and days 1, 3, and 4 p.i. and when
paralysis was observed. In preparation of tissues for virus
titration, we initially extirpated the abdominal organs and
cervical lymph nodes. Thereafter, we extirpated the brains
and olfactory bulbs, and finally the maxillary tissue, which
is separated from the overlying skin and from the mandib-
ular tissue. Histologically, the maxillary tissue consists of
N. Nagata et al. / Virology 321 (2004) 87–10094the nasal cavities and paranasal sinuses lined by columnar
and olfactory epithelium and focally the stratified squamous
epithelium.
In TgPVR21 inoculated with OM1, poliovirus titers were
slightly increased in the maxillary tissue including the nasal
cavity (Fig. 6A). The virus was isolated from the Peyer’s
patch at 6 h p.i. and from the cervical lymph nodes and
spleens at day 1 p.i. The virus was constantly present in
CNS from day 3 p.i. and increased up to 108 CCID50/g of
wet tissue at day 5 p.i. The titers in CNS correlated well
with immunohistochemical detection of viral antigens and
neurological manifestations. The virus in the plasma was
detected later than its appearance in CNS and only in the
paralytic phase.Fig. 6. Virus titration of poliovirus-infected TgPVR21 following intranasal inoculat
3, and 4 p.i. (n = 3). In addition, TgPVR21 showing paralysis were also examine
sacrificed on days 4, 5, and 7 p.i. (n = 3).Max, maxilla; L/N, lymph node; PP, Peyer’sThe virus titers of non-transgenic BALB/c mice inocu-
lated with OM1 were examined at 6 h and days 1, 3, and 5
p.i. A transient highest titer was observed at 6 h after
inoculation in the nasal cavities (104.7 CCID50/g) and
Peyer’s patch (104.0 CCID50/g) and gradually decreased in
the following days. The virus amount was less than a
titratable level in the lymph nodes at 6 h and day 1 p.i.
The virus was not isolated from the brain and spleen.
No lethal outcome in TgPVR21 following intranasal
inoculation of attenuated poliovirus
Thirty TgPVR21 were inoculated with 2 Al of inoculum
containing 105 or 106 CCID50 of Sabin 1 strain. Noion. (A) TgPVR21 inoculated with OM1were sacrificed at 6 h, and on days 1,
d around day 5–7 p.i. (n = 4). (B) TgPVR21 inoculated with Sabin 1 were
patches; BS, brainstem; CC, cervical spinal cord; and LC, lumbar spinal cord.
Fig. 7. RT–PCR detection of replicative intermediates of poliovirus in the maxillary tissue of TgPVR21. (A) A sense-strand primer for reverse transcription
was designed based on the noncoding sequence. PCR amplification targeted the P1 sequence and yielded a 153-bp product. (B) Two-microliter volume of
polioviruses, F113 (Sabin 1) (lanes 1–9) and OM1 (lanes 10–18), were intranasally inoculated into BALB/c (lanes 1–3 and 10–12), IQI (lanes 4–6 and 13–
15), and TgPVR21 (lanes 7–9 and 16–18). Amplified product was observed only in TgPVR21 infected with F113 (lane 8) and OM1 (strongly in lanes 16 and
17 and weakly in 18). P, N and M are positive control, negative control and 100 base molecular weight markers, respectively.
Table 5
Virus-specific IgG levels in the sera of three strains of mouse after
intranasal inoculation of vaccine and neurovirulent strains of poliovirus 1
on day 21 p.i.
Route/dose Poliovirus-specific IgG in the serum
Sabin 1 OM1
BALB/c (n = 7) < 2 < 2
IQI (n = 7) < 2 < 2
TgPVR21 (n = 7) 28.71F 1.70 28.5F 1.29
a
Seven mice of two non-transgenic mouse strains (BALB/c and IQI) and
TgPVR21 were intranasally inoculated with Sabin 1 or OM1 and the serum
antibody was measured on day 21 p.i. using ELISA.
a The sera were available for the measurement in only four mice survived
after OM1 inoculation. The other three died.
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mice. In addition, no histological changes were detected in
the autopsied mice. The virus titers in tissues of TgPVR21
inoculated with Sabin 1 were investigated on days 4, 5,
and 7 p.i. The virus was titratable only in the maxillary
tissue and lymph nodes (Fig. 6B). On day 4 p.i., the virus
titer in the maxillary tissue was more than 104.7 CCID50/g
suggesting the viral replication in the maxillary tissue.
However, the virus could not be isolated from CNS,
spleen, blood cells, or plasma, but was isolated a low titer
from the cervical lymph nodes, to which lymph drains
from the nasal cavities.
To confirm the replication of Sabin 1 strain in the
nasal cavities, we performed a reverse transcriptase-poly-
merase chain reaction (RT-PCR) analysis to detect the
negative-stranded RNA transcribed from poliovirus
genomes. Groups of three TgPVR21, BALB/c, and IQI
mice were intranasally inoculated with Sabin 1 or OM1.
Three days post-inoculation, the maxillary tissue was
carefully excised from the head, avoiding contamination
with CNS tissue, and was analyzed. One of the three and
all of the three TgPVR21, inoculated with Sabin 1 and
OM1, respectively, were positive for the replication inter-
mediate (Fig. 7).Intranasal challenge infection of OM1 in survived TgPVR
after inoculation of Sabin 1
We determined the serological response in TgPVR and
non-transgenic mice after intranasal inoculation of Sabin 1
and found that only TgPVR showed an marked increase in
poliovirus-specific IgG in the serum on day 21 p.i. (Table
5), although no increase was observed regarding the neu-
tralizing antibody (data not shown). This serological data
Fig. 8. Survival of TgPVR21 following intranasal challenge of OM1. Ten
TgPVR21 were inoculated with Sabin 1 at 106 CCID50/mouse (light) three
times with 3 weeks interval. Three weeks after the final inoculation, these
and naive (bold) mice were intranasally challenged with OM1 at 107
CCID50/mouse and their manifestation was observed daily for 2 weeks.
N. Nagata et al. / Virology 321 (2004) 87–10096confirm that the mice bearing hPVR are only infected with
poliovirus although poliovirus-specific IgA could not be
detected in the nasal wash obtained from mice inoculated
with Sabin 1 or OM1 on day 21 p.i.
Then, we performed challenge infection of neurovirulent
poliovirus in TgPVR after triple intranasal inoculation of
Sabin 1. The experiments were examined three times. The
first result (Fig. 8) and other two experiments using 10 mice
for each group brought a similar protection pattern in
intranasally immunized mice (10%, 20%, and 0% morbid-
ity), in contrast to 50%, 60%, and 60% morbidity in mock
group. From this result, triple mucosal inoculation with the
attenuated poliovirus in this model was apparent to provoke
partial immunity against intranasal poliovirus infection.Discussion
Similarity in the susceptibility to poliovirus of monkeys and
TgPVR21
In this study, we revealed the susceptibility of TgPVR21
to neurovirulent poliovirus inoculated through the intranasal
route and the lower susceptibility to infection via other
mucosal routes as reported previously (Koike et al., 1991a).
Another transgenic mouse line expressing hPVR under the
control of the promoter of rat intestine fatty acid binding
protein, which is specific for intestinal cells and M cells
(TgFABP-PVR), was also shown to be resistant to infection
by the oral route (Zhang and Racaniello, 1997). Bodian and
Howe (1940) demonstrated that rhesus monkeys are sus-
ceptible to poliovirus type 1 inoculated through the intra-
nasal route. Localization of poliovirus-infected cells in CNS
is also similar between TgPVR21 and monkeys, particularly
the presence of poliovirus in the motor cortex (Barnhart et
al., 1948; Bodian, 1949; Nagata et al., 2001). Thus,
TgPVR21 and monkeys are suggested to have similarsusceptibilities to poliovirus infection. In this study, we
could not explain why the mice and monkeys were not
susceptible following intraoral and intragastric inoculations.
However, it was apparent that poliovirus could infect the
upper respiratory tract of TgPVR21 mice and neurovirulent
strains invaded into CNS.
Initial replication of poliovirus in the nasal cavity
It was demonstrated that intranasal infection is sufficient
to cause CNS involvement and there was no marked delay
in the appearance of neurological symptoms among mice
infected with different inoculum volumes. The incubation
period before the onset of neurological manifestations was
2–3 days longer than that following direct inoculation of
virus into CNS or muscle tissues. Previous studies using
different lines of TgPVR showed that neurological mani-
festations developed 2–3 days after intracerebral inocula-
tion (Horie et al., 1994; Ren et al., 1990) and intraspinal
inoculation (Abe et al., 1995a) and 2 days after intramus-
cular inoculation (Ohka et al., 1998; Ren and Racaniello,
1992b). This difference in the incubation period suggests
that the virus first replicates in the extraneural tissue and
then invades CNS.
Previous studies to detect polioviruses in TgPVR could
not identify the infected cells in tissues other than CNS and
muscle by in situ hybridization (Ren and Racaniello, 1992a,
1992b) because of a low copy number of the virus in the
extraneural tissues. However, we could identify that polio-
virus initially infect columnar cells of nasal mucosa (Fig. 2)
by high-sensitive immunohistochemistry after the antigen-
retrieval method and RNA in situ hybridization. These
findings explain the gradual increase in the virus titer in
the nasal cavities and presence of negative-stranded RNA
transcripts of poliovirus in the maxillary tissue following
intranasal inoculation of OM1 and Sabin 1.
Virus spread into CNS
Following viral replication in the nasal cavity, the neural,
hematogenous, and lymphatic routes are suspected to be the
routes of viral spread into CNS. The hematogenous pathway
is negligible as a route for viral spread because poliovirus
could not be isolated from the blood cells and plasma except
in the terminal stage of infection although there is a
possibility of undetectable transient viremia. The plasma
titer of poliovirus was only 103.5 CCID50/ml (Fig. 3), which
was 1/10 to 1/1000 of the titer required to cause neural
involvement following intravenous administration (Yang et
al., 1997).
Recently, Crotty et al. (2002) discussed the mucosal route
to CNS in their new transgenic mouse line carrying a PVRy
cDNA driven by a ubiquitous promoter of h-actin. This
mouse line was susceptible to poliovirus and developed
paralysis following intranasal inoculation. Histological ex-
amination of paralytic mice after intranasal inoculation
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brain stem, and spinal cord. They suggested that poliovirus
spread through the olfactory system because of quick
appearance of infected cells in the olfactory. The nasal
cavity is innervated by various nerve endings including
the olfactory nerve. In the present study, we detected
poliovirus-infected cells in the mucosal epithelium of the
nasal cavity and the vestibular nuclei in the brain stem but
not in the olfactory bulb and other brain nerve nuclei in the
early stage. The localization of infected cells in CNS was
well correlated with the neurological manifestations of
TgPVR21. Thus, if the virus is spread via neural route,
trigeminal and/or vestibular afferent routes might play an
important role in spread in TgPVR21 because of initial
presence of the viruses in this brainstem, and the olfactory
system might not be involved because of absence of viral
antigens, genome, and transcripts in this system in the early
stage of infection.
However, the lymphatic route possibly plays an impor-
tant role in pathogenesis because poliovirus could be
isolated from the regional lymph nodes at days 1–4 p.i.
Mononuclear cells of TgPVR were demonstrated to be
capable of supporting poliovirus replication in low yield
(Freistadt and Eberle, 2000), although we could not verify
the presence of poliovirus in the peripheral blood mononu-
clear cells of TgPVR21 by virus isolation (data not shown).
Virus replication was observed in vitro cultures of human
mononuclear cells (Eberle et al., 1995) and it was markedly
inefficient in Sabin 1-infected cells in comparison with the
virus yield in cells infected with neurovirulent strains
(Freistadt and Eberle, 1996).
Paralysis caused by the neurovirulent but not by the vaccine
strain
It was also demonstrated that only the neurovirulent
strain of poliovirus type 1 causes paralysis in TgPVR21
mice following intranasal inoculation. The replication of
the neurovirulent strain in CNS was confirmed by the
presence of poliovirus-specific antigen. The Sabin I vac-
cine strain did not cause any neurologic manifestations
even at 106 CCID50 and the virus could not be isolated
from CNS of infected mice. Neutralizing antibody to
poliovirus was not detected in the serum 3 weeks p.i.
Even after two intranasal inoculations of Sabin I, we could
not detect the neutralizing antibody in TgPVR21, but the
increase of specific IgG antibody in the serum (Table 5).
From these data, we performed triple intranasal inoculation
of Sabin 1 and subsequent challenge with OM1 and found
that these mice acquired immunity against poliovirus
infection.
Paradigm of mucosal infection of poliovirus in TgPVR21
Recent progress in the field of mucosal immunology
has revealed marked differences in the immune response ofhosts following mucosal and parenteral contact with anti-
gens. This model of intranasal inoculation of poliovirus in
TgPVR21 has a great advantage to investigate the efficacy
of mucosal immunization of poliovirus. Since we could
differentiate neurovirulent and attenuated strains of polio-
virus by their neurological manifestations and survival in
this study, the model presented will be valuable for
evaluating the neurovirulence of clinical isolates and
qualification of vaccination against emerging isolates of
vaccine-derived mutants in Haiti and Philippines (Kew et
al., 2002).Materials and methods
Animals
Female and male special pathogen-free (SPF) transgenic
mice, IQI TgPVR21 (TgPVR21), aged 5–14 weeks, were
bred under carefully monitored conditions. TgPVR21 mice
were heterozygous for the human PVR transgene. These
heterozygotes were born from a TgPVR21 homozygote
mother and non-transgenic IQI father. In addition, two
inbred strains of mice, BALB/c and IQI, aged 6–7 weeks,
were also purchased from Charles River Co, Japan, and the
Central Institute for Experimental Animals, Japan, respec-
tively, as negative controls.
Virus and cells
We used an infectious clone of a neurovirulent Maho-
ney strain of poliovirus type 1, PV1 (M) OM (OM1)
(Shiroki et al., 1995) to prevent variations in the inocu-
lated virus, and an attenuated strain of Sabin type 1, a
Japanese reference strain, F113, as a control. Strain F113
was also used for determination of neutralization antibody
titers. Virus stocks of both strains were prepared in Vero
cells with 2% fetal calf serum in Eagle’s minimum
essential medium. CCID50 of both stocks was titrated in
HEp-2c cells according to the WHO manual (WHO,
1997).
Inoculation
Viral suspension was inoculated into mice by intragas-
tric, intraoral, and intranasal routes. Following inoculation,
the mice were observed daily for 3 weeks. When the mice
became moribund, the mice were deeply anesthetized. The
blood obtained at autopsy was used for the antibody assay
and virus titration. The intestinal contents were also
obtained.
Intragastric inoculation
The mice were starved overnight and 100 Al virus
suspension was inoculated into the stomach using a gavage
needle.
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Mice accustomed for 2 days to drinking 150 Al of 20%
sucrose solution through a micropipette were starved over-
night and inoculated with 150 Al of virus suspension diluted
with 20% sucrose solution.
Intranasal inoculation
The virus solution was inoculated into both nostrils under
deep anesthesia achieved using 3 mg of amobarbital/mouse.
Neutralizing antibodies
Serum samples, obtained at sacrifice, were stored at 80
jC until analysis. Serum titers of neutralization antibody to
poliovirus type 1 were determined by a microplate method
(WHO, 1997). Briefly, the serum was diluted with Eagle’s
minimum essential medium to 1:4 to 1:512, and then
incubated with 100 CCID50 of strain F113 for 2 h at 36
jC. Thereafter, the serum was inoculated with 1104 HEp-
2c cells. The cells were observed for 6 days for the
appearance of cytopathic effects (CPE) of poliovirus.
ELISAs
Serum samples were obtained at sacrifice and were
stored at 80 jC until analysis. The antibodies against
poliovirus type 1 were measured by ELISA following the
method of Tamura et al. (1998). Wells of ELISA plates
(Costar, Cambridge, MA) were coated with 1 Ag/ml of
inactivated Sabin strain of poliovirus type 1 (kindly supplied
from the Japan Poliomyelitis Research Institute, Tokyo,
Japan) and blocked with 1% bovine serum albumin in
PBS. After serum samples or nasal washings were reacted,
the plates were incubated with biotin-labeled goat anti-
mouse IgA (Southern Biotechnology Associates, Birming-
ham, AL), anti-mouse IgG (Jackson ImmunoResearch Lab-
oratories, West Grove, PA) or anti-mouse IgM (Vector,
Burlingam, CA), in combination with alkaline phospha-
tase-conjugated streptavidin (Invitrogen, Carlsbad, CA).
After incubation with p-nitrophenyl-phosphate (Sigma, St.
Louis, MO), the optimal density (OD) of the wells was read
at 410 nm by use of an ELISA reader (Labsystems Multis-
kan MS, Labsystem, Finland). A sample was diluted 1/22 to
1/213 and considered positive when the OD was above the
cut-off levels (mean + 3 SD of the samples of non-immu-
nized mice).
Histology
Following sacrifice under deep anesthesia using ether
and venipuncture, the tissues, including the brain and spinal
cord, were excised, fixed in 10% formalin in phosphate
buffer and embedded in paraffin. Paraffin sections, 6 Am in
thickness for CNS and 3 Am in thickness for other tissues,
were stained with hematoxylin and eosin and with Luxol
fast staining.Immunohistochemistry
Immunohistochemical detection of the capsid protein of
poliovirus was also performed in paraffin sections according
to the method previously described (Koike et al., 1991a,
1991b; Nagata et al., 2001). Briefly, sections deparaffinized
in xylene and re-hydrated in ethanol were treated with
0.25% trypsin solution containing 0.5% CaCl2 for 30 min,
then incubated in 1% hydrogen peroxide in methanol to
block endogenous peroxidase activity. Thereafter, sections
were incubated with normal goat serum for 5 min and
overnight at 4 jC with rabbit serum recognizing the capsid
proteins of poliovirus. The sections were incubated with
biotin-conjugated anti-rabbit IgG, following which strepta-
vidin-peroxidase was applied. The peroxidase reaction was
developed in diaminobenzidine with hydrogen peroxide.
Nuclei were counterstained using methyl green. To increase
the sensitivity for detection of poliovirus antigens in the
nasal mucosa, we performed the antigen retrieval in 0.01 M
citrate buffer (pH 7.0) at 121 jC for 15 min before
immunohistochemical procedures using the GenPoint sys-
tem (DakoCytomation, Carpinteria, CA).
In situ hybridization
A BamHI–BamHI fragment (nt. 221–670) of poliovirus
cDNA was inserted into BamHI site of pBluescript KS in
both orientations. After digestion of these recombinants
with EcoRI, in vitro transcription was performed using T7
RNA polymerase and NTP mixture containing digoxigenin
(DIG)-UTP (Roche Diagnostics, Indianapolis, IN) as sub-
strates. Mice were fixed by perfusion and overnight immer-
sion of and in 4% paraformaldehyde/PBS at 4 jC. Fixed
tissues were embedded in paraffin after dehydration and
sectioned. In situ hybridization was carried out as described
previously (Koike et al., 1994). The hybridized DIG-labeled
RNA probes were visualized using a DIG Nucleic Acid
Detection Kit (Roche Diagnostics) by alkaline phosphatase
reaction with substrates of NBT/BCIP. After the reaction,
sections were counterstained with methyl green.
Virus titration
Tissues obtained at autopsy were homogenated and
resuspended in Eagle’s MEM to 10% or 20% w/v. One
hundred microliters of the homogenate was inoculated into
HEp-2c cells, which were observed for the appearance of
CPE for 7 days. Then, the medium was further passaged to
re-confirm. Homogenates positive for CPE were titrated on
Hep-2c cells using CCID50 by method of Behrens-Ka¨rber
(WHO, 1997).
Detection of replication intermediates of poliovirus
The presence of the negative-stranded RNA transcript of
poliovirus 1 in the inoculated tissue was determined by RT-
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enized in TRIZOL (Invitrogen). RNAwas extracted accord-
ing to the manufacturer’s instructions. Negative-stranded
RNAs of poliovirus 1 was reversely transcribed using a
sense oligonucleotide, PV1/302/F, 5V-AGA GTG TAG CTT
AGG CTG ATG AGT-3V, using a First Strand cDNA
synthesis kit (Roche Diagnostics) according to the manu-
facturer’s instructions. Thereafter, PCR was performed us-
ing an oligonucleotide primer pair (forward PV1/964/F: 5V-
GGC TTG CGG GTA TAG CGA TAG A-3V; reverse PV1/
1120/R: 5V-GTC TGG TTC TGT CGG CTG GTC CAC-3V;
estimated product size, 157 bp) and an Expand High
Fidelity PCR system (Roche Diagnostics). Forty cycles of
amplification consisting of 30 s denaturation at 94 jC, 60 s
annealing at 58 jC, and 90 s elongation at 72 jC were
performed. The amplified product was analyzed in a 3%
agarose gel by constant voltage electrophoresis.Acknowledgments
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